Evaluation of Upadacitinib efficacy in the treatment of Atopic Dermatitis of sensitive areas

: The treatment of atopic dermatitis (AD) affecting sensitive areas (head and neck, hands and genitalia) remains a significant challenge, even with the advent of the current range of biologic therapies. Recently, Upadacitinib, a selective inhibitor of the JAK1 enzyme, has been approved for the treatment of moderate to severe atopic dermatitis (AD) and promising results have been observed in the treatment of AD located in sensitive areas. The aim of this multi-center observational study was to better characterize the effectiveness of Upadacitinib in sensitive areas, using specific clinimetric tools. We enrolled 74 adult patients (41 women and 37 men, with a mean age of 33.8 years), affected by moderate to severe AD with the involvement of at least one sensitive area. They were treated with Upadacitinib for at least 16 weeks. Over the course of the 52-week study period, Upadacitinib demonstrated remarkable efficacy in the reduction of AD symptoms and associated clinical manifestations in sensitive areas.